Skip to Content

    Alexion has had its share of controversies. Concerns over the company’s sales practices have dogged the rare-disease biotech and led to major C-suite shake-ups. But the firm has attempted to rebuild trust among patients and investors, and has acquired or partnered with upstart biotechs such as Syntimmune and Caelum Biosciences. Though these deals are filled with early-stage and unproven assets, many investors still see upside.

    Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.

    Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

    Company Information

    Overall Score1.3
    Sector
    Health Care
    Industry
    Biotechnology
    CEO
    Ludwig Hantson
    Websitehttps://www.alexion.com
    HQ Location
    Boston
    Country
    U.S.
    Revenues ($M) (Past 12 Months)$4,499
    Profits ($M) (Past 12 Months)$1,334
    Market Value as of Oct. 9, 2019 ($M)$21,266
    Employees2,656

    Refinitiv Sustainable Leadership Monitor

    placeholder